http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김창엽,김은혜,오연경,오태영,Kim, Chang-Yeop,Kim, En-Hye,Oh, Yeon-Kyeung,Oh, Tae-Young 대한물리치료과학회 2012 대한물리치료과학회지 Vol.19 No.3
Background and Purpose : This study was to analysis effects of muscle fatigue on error of elbow joint sense. Methods : A total 19 healthy student(men = 10, women = 9) who did't have any problem of musculoskeletal system in upper extremities participated this study. we divided two groups into young group(n = 10, $19.67{\pm}.5$) and old group(n = 9, $28.56{\pm}1.5$). In order to evoke muscle fatigue of elbow flexor, we used Biodex, and participations performed concentric contraction of elbow flexor 150 numbers as well as we measured error of joint sense using by Biodex. We collected data just after, 30min, 2hour, 24hour after evoked muscle fatigue, and we finanlly acquired average value of three times measured joint sense of elbow joint. And we calculated value of percentage of error of joint sense. We analyzed collected data by repeated ANOVA, ANOVA using by SPSS ver.12.0 program. Result : This study showed that there was no significantly effects between groups and within groups, we could see that there was significantly difference among duration by each group of age, and sex(p<.05). Conclusion : The error of joint position sense presented highest value just period after evoked muscle fatigue compared after 30 min, 2 hours, 24 hours, and we can't find out interaction between duration and age and sex.
Alemtuzumab을 이용한 이차성 순적혈구 빈혈의 치료
박혜민 ( Hye Min Park ),임재욱 ( Jae Uk Im ),박주환 ( Ju Hwan Park ),김은혜 ( En Hye Kim ),전홍길 ( Hong Gil Jun ),박재후 ( Jae Hoo Park ),김혁 ( Hawk Kim ) 대한내과학회 2013 대한내과학회지 Vol.85 No.2
Pure red cell aplasia (PRCA) in adults is usually idiopathic, although some underlying conditions can cause PRCA. Immunosuppressive therapy (IST) is used to treat PRCA, but IST has side effects and may fail. The anti-CD52 monoclonal antibody alemtuzumab (ALM) was recently used to successfully treat therapy-resistant PRCA. We herein report successful treatment of secondary PRCA after erythropoietin therapy using ALM and cyclosporin A (CsA) in one patient. The total dose of ALM was 60 mg over 3 days (10, 20, and 30 mg, respectively) plus CsA for at least 6 months. The patient achieved a complete response 18 months after ALM-CsA treatment and his treatment could be changed to a different erythropoietin stimulating agent. (Korean J Med 2013;85:214-217)